FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For May 2021
Commission File Number: 001-11960
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Indicate by check mark whether the registrant file or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
EXPLANATORY NOTE
In connection with the issuance by AstraZeneca PLC of $1,400,000,000 0.300% Fixed Rate Notes due 2023 and $750,000,000 3.000% Fixed Rate Notes due 2051, and the issuance by AstraZeneca Finance LLC of $1,600,000,000 0.700% Fixed Rate Notes due 2024, $1,250,000,000 1.200% Fixed Rate Notes due 2026, $1,250,000,000 1.750% Fixed Rate Notes due 2028 and $750,000,000 2.250% Fixed Rate Notes due 2031 fully and unconditionally guaranteed by AstraZeneca PLC, AstraZeneca PLC is filing the following documents solely for incorporation into the Registration Statement on Form F-3 (File No. 333-256406):
Exhibit List
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ASTRAZENECA PLC |
Date: May 28, 2021 | By: | /s/ Adrian Kemp |
Name: Adrian Kemp | ||
Title: Company Secretary |
3